Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Outline of Final Research Achievements |
We have demonstrated the possible involvement of Osteoprotegerin (OPG) in the prevention of AAAs through inhibition of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). After the induction of AAA by CaCl2 treatment, diameters of aorta were significantly increased with destruction of elastic fibers in the media in Opg knockout (KO) mice, as compared to wild-type mice. Moreover, up-regulation of TRAIL expression was observed in the media by immunohistochemical assay. In smooth muscle cells (SMCs) culture system, both the TRAIL-induced expression of matrix metalloproteinase-9 and the chemoattractive effect of TRAIL on SMCs were inhibited by OPG. These data suggest that Opg may play a protective role in the development of AAA through its antagonistic effect on Trail.
|